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IBD BioResource: an open-access 
platform of 25 000 patients to 
accelerate research in Crohn’s 
and Colitis
Miles Parkes,   On behalf of the IBD BioResource Investigators
Give us the tools and we will finish the job
-Winston Churchill
An alliance of clinicians, academics, 
research nurses, funders, coordinators, 
programmers and, most importantly, 
patients has come together in the UK to 
deliver a powerful new platform to accel-
erate Crohn’s and Colitis research—the 
inflammatory bowel disease (IBD) BioRe-
source. As part of the National Institute 
for Health Research (NIHR) BioResource 
for translational research, 25 000 patients 
in over 90 hospitals UK-wide have signed 
up since we launched in January 2016 
(figure 1). All have detailed phenotypes 
databased including Montreal classi-
fication,1 treatment response history 
(updated annually), surgical history and 
comorbidities (see IBD BioResource 
panel descriptive, Clinical data collection 
sheet and Health and Lifestyle question-
naire). Serum, plasma and DNA samples 
are banked; and genome-wide genetic 
profiling undertaken. Participants’ data 
and samples can be studied, and they 
themselves surveyed or recalled for resam-
pling or downstream studies (see figure 2). 
Critically, such studies can be led by any 
UK or overseas investigator whether from 
the worlds of clinical research, pharma-
covigilance, science or industry.
What Is the IBD BIoResouRCe foR
A key motivation is to leverage recent 
genetics advances, and by understanding 
the functional impact of IBD-associated 
gene variants accelerate translation of 
the new knowledge for clinical benefit. 
Beyond this, it is increasingly evident 
that the IBD BioResource can facilitate 
a wide spectrum of research. This might 
include anything from mining existing 
data or samples or surveying the cohort 
regarding outcomes of newly licensed 
treatments, to pharmacogenetic research. 
It could also be used to expedite recruit-
ment to intervention studies, including 
experimental medicine and conventional 
drug trials.
Gene discovery in Crohn’s disease and 
ulcerative colitis has placed these condi-
tions at the forefront of the field of common 
disease genetics. As the UK IBD Genetics 
Consortium we have, through national 
and international collaboration, helped 
deliver a number of landmark studies in 
IBD.2–14 More than 240 confirmed IBD 
susceptibility loci have been identified to 
date. New druggable pathways continue to 
be identified and new pathogenic insights 
continue to accrue,4 particularly from 
those loci where the causal variants have 
been identified and functionally charac-
terised. Examples of the latter include the 
association between IBD and the R381Q 
variant in the interleukin 23 receptor and 
between CD and the T300A variant in the 
autophagy gene ATG16L1.15–17
For most IBD risk loci, however, the 
causal genes and causal variants await 
identification. There are instances of 
hard-fought progress, with dissection of 
individual loci allowing new genes to be 
characterised and new biological insights 
gained18 19; and using innovative genetic 
‘fine mapping’ techniques it has been 
possible to refine ~20% of risk loci to a 
single variant.2 However, functional char-
acterisation of the latter is awaited, and is 
made all the more challenging by the fact 
that most are non-coding (regulatory). 
Furthermore, more than 50% map to 
genomic regions lacking homology with 
any known functional motif. The prize 
may be new biological insight not just 
about IBD pathogenesis but potentially 
also new understanding of the regulation 
of gene transcription, but no number of 
DNA samples can deliver this. Without 
recourse to mouse models or genetically 
manipulated cell lines, with all their prob-
lems, investigators will be able to use the 
IBD BioResource to access and resample 
cohorts of patients homozygous for risk 
and wild-type alleles at any locus. Already, 
despite only having recently reached 
maturity, such ‘stage 2’ recall-by-geno-
type studies are in progress. These are 
interrogating the functional impact of 
cytokine polymorphisms, non-coding 
RNA’s and HLA variants implicated in our 
genome wide association studies (GWAS), 
to better understand how these contribute 
to IBD pathogenesis and to specific 
subphenotypes.
Critical to the success of the IBD BioRe-
source will be the willingness of patients 
to participate in annual surveys (to gather 
long term data re treatment outcomes 
etc) and stage 2 studies. It is early to be 
drawing conclusions, but in stage 2 studies 
to date 30%–60% of eligible participants 
have agreed to help. Maintaining engage-
ment with patients and potential stage 2 
users is clearly a key role of the team of 
four IBD BioResource coordinators and 
one data manager. As well as running 
the annual surveys, they maintain the 
website ( www. ibdbioresource. nihr. ac. 
uk), circulate newsletters and promote 
activities through social media (Twitter 
and LinkedIn). Over the next 5 years, it 
is anticipated that longitudinal data from 
surveys will be substantially augmented by 
access to NHS digital and potential collab-
orations with the IBD Registry and Health 
Data Research UK, to minimise the risk of 
participants being lost to follow-up.
In addition to its recall/resample func-
tionality, the IBD BioResource will also 
be used as the substrate for a new suite 
of genetics analyses. There is still more 
mileage in GWAS for risk variants: as the 
IBD dataset expands so the number of loci 
detected will increase in linear proportion, 
and new insights gained.20 Beyond GWAS 
increasing attention is turning to exome 
and whole genome sequencing, particu-
larly to ascertain low frequency risk vari-
ants of potentially greater effect size than 
are typically identified by GWAS.3 These 
may contribute to the ‘missing heritability’ 
of IBD and other common diseases.21 
Two limiting factors to date have been 
sequencing costs and the need for very 
large sample sizes to detect rare variant 
associations with statistical confidence. 
Both are becoming tractable. All IBD 
BioResource participants will undergo 
50x exome sequencing or 20x genome 
sequencing and the data will be meta-an-
alysed with other datasets in the interna-
tional IBD genetics consortium in well 
powered studies; and the results made 
available to the research community.
tRanslatIonal aspeCts
As well as identifying susceptibility genes, 
there is increasing interest in identi-
fying biomarkers for clinically relevant 
outcomes such as prognosis and treatment 
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response, the aim being to deliver on the 
promise of personalised medicine. This 
requires detailed phenotypes on large 
sample sets—something the IBD BioRe-
source has, with 95% completion of core 
data fields on the first 24 000 participants. 
Lee et al previously used GWAS to identify 
loci associated with Crohn’s disease prog-
nosis22; and blood monocytes from geno-
type-selected NIHR BioResource subjects 
to interrogate the function of a FOXO3 
polymorphism.23 The expanding IBD 
BioResource dataset should identify more 
markers associated with disease course 
and enable development of progressively 
more accurate ‘polygenic scores’ for prog-
nosis. The latter use the power of genome-
wide data (rather than just genome-wide 
significant hits), potentially combined 
with environmental modifyers such as 
smoking, to substantially improve predic-
tive accuracy.24 This could be used at the 
time of IBD diagnosis to identify individ-
uals destined for a complex disease course 
with multiple flares, perhaps warranting 
early and aggressive therapy.
Regarding treatment outcomes, pharma-
cogenetic analyses have recently identified 
a number of clinically important associ-
ations. Thus, NUDT15 polymorphisms 
are associated with thiopurine-induced 
leucopenia both in Asians and Euro-
peans25 26; and human leukocyte antigen 
(HLA) DRB1*0701 is associated with risk 
of thiopurine pancreatitis.27 Other work 
lead by Tariq Ahmad in Exeter, including 
samples from the IBD BioResource, has 
identified strong association between 
HLA DQA1-05 (found in 40% of people 
of European origin) and immunogenicity 
to anti tumour necrosis factor (TNF) 
therapy.28 Studies to demonstrate the 
utility of testing for these in the IBD clinic 
is a near-term objective for IBD BioRe-
source investigators.
Future pharmacogenetic studies will 
also benefit from the scale of the IBD 
BioResource. By recruiting from hospital 
clinics, it is biased towards more severely 
affected patients. Thus >13 000 have been 
treated with thiopurines and >9000 with 
anti-TNF therapy, all with detailed treat-
ment outcomes recorded. Through the 
IBD BioResource, all participants can be 
recontacted or recalled if more detailed 
information or more samples are required. 
Even relatively recently introduced thera-
pies are strongly represented, for example, 
over 1400 participants have received 
vedolizumab—and through an annual 
‘treatment update’ survey, we expect to 
see this number climbing rapidly. We thus 
have a clear opportunity to better under-
stand how these treatments are being used 
in routine practice, and for further phar-
macogenetic analyses, for example, of 
treatment response. There may also be a 
role for the IBD BioResource in pharma-
covigilance for new therapies.
suppoRtIng InteRventIon stuDIes 
anD DRug tRIals
Can the IBD BioResource directly support 
intervention studies, including drug trials? 
We believe so. Later this year, it will be 
used to recruit to the IBD BOOST study, 
surveying 12 000 patients and then 
recruiting 1180 with self-reported symp-
toms of fatigue, pain and/or urgency for 
different interventions. There is also 
potential utility for drug trials recruit-
ment. There is widespread recognition 
that drug development takes too long, is 
too costly and potentially high risk.29 With 
the recent expansion of licensed IBD ther-
apies industry may see the cost of devel-
oping a new drug, particularly one that 
ends up as fourth or fifth line therapy, as 
too great—and might shelve some of the 
potentially valuable new treatments.30 
Different strategies are required, poten-
tially including experimental and preci-
sion medicine to investigate subgroups 
of patients who have distinct pathogenic 
pathways and in whom drugs which target 
those pathways may demonstrate high 
efficacy (hence warranting earlier use in 
such biomarker-defined subsets). The IBD 
BioResource, with its detailed genome-
wide data, is ideally positioned to support 
such studies.
At a more general level, the IBD 
BioResource is well placed to accelerate 
recruitment to conventional phase 3 
studies—widely regarded as a major bottle-
neck in drug development. This should be 
of great interest to the pharma industry 
and clinical research organisations. Poten-
tial participants meeting inclusion criteria 
for a particular study (identified from the 
IBD BioResource database of phenotypes 
and drug histories) and under a trial site 
hospital can be provided with trial details 
figure 1 IBD BioResource recruitment in over 90 hospitals in the UK. IBD, inflammatory bowel disease.
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and notified that if their IBD is flaring and 
they are interested they should contact the 
research nurse at their site. Many patients 
are only too willing to participate in 
research but a major block is giving them 
the opportunity.31 Inherent to the problem 
is that most drug trial recruitment happens 
in clinic, but requires the clinician meeting 
the patient in flare to know about the 
study, be aware of inclusion criteria and 
to match these up to the patient in front 
of them. This presupposes an alignment of 
knowledge, time and motivation in busy 
clinicians, and all too often one or more of 
these is lacking. Having a large cohort of 
research-engaged IBD BioResource partic-
ipants who have consented to screening of 
their medical records and can be contacted 
directly regarding research should help 
circumvent this bottleneck.
the futuRe
A key goal over the next 5 years is to 
recruit an inception cohort of 1000 indi-
viduals newly diagnosed with IBD who will 
undergo more detailed sampling (including 
stool, biopsy tissue and whole blood for 
RNA—unconfounded by the effects of drug 
treatment) and longitudinal follow-up. In 
due course, this will facilitate and expand 
existing research into the determinants, 
predictors and biomarkers of disease course 
and treatment response.32 33
The IBD BioResource has more than 
90 hospitals participating UK-wide, and 
is now recruiting at ~1000 patients per 
month (figure 1). With 25 000 highly 
characterised patients already signed up, it 
is very definitely ‘open for business’ and 
now able to support and expedite a wide 
range of studies. What began as a resource 
to enable post-GWAS studies has become 
figure 2 How the IBD BioResource works. HES, Hospital Episode Statistics; HSCN, Health Social Care Network; IBD, inflammatory bowel disease; 
NHS, National Health Service.
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a wider multidimensional platform ready 
for use by the global IBD research commu-
nity. Its job is to accelerate IBD research 
across all domains, improve treatments 
and outcomes, and perhaps one day ‘finish 
the job’ by achieving a cure. We are keen 
to see this tool used!
to apply to use the IBD 
BIoResouRCe please vIsIt
https:// BioResource. nihr. ac. uk/ researchers/ 
researchers/ application- process/
Enquiries re its use to  ibd@ bioresource. 
nihr. ac. uk
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